<DOC>
	<DOCNO>NCT00964262</DOCNO>
	<brief_summary>The purpose study evaluate safety , pharmacokinetics , pharmacodynamics SR exenatide ( PT302 ) healthy subject .</brief_summary>
	<brief_title>A Study Evaluate Safety Pharmacokinetics/Pharmacodynamics Sustained Release ( SR ) Exenatide</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Healthy male subject age 2045 year screen Body weight 50 kg , inclusive , within 20 % ideal body weight Has present illness medical history hepatic , renal , respiratory , cardiovascular disease , blood tumor , mental disorder , endocrinologic disorder , especially diabetes mellitus Has sign symptom history relate acute chronic pancreatitis Has know allergy hypersensitivity exenatide drug aspirin , antibiotic , Has ever expose exenatide Shows SBP &gt; = 150 mmHg &lt; = 90 mmHg DBP &gt; = 100 mmHg &lt; = 50 mmHg Has presence history drug abuse Uses prescription drug , herbal medicine within 2 week OTC drug vitamin within 1 week prior study drug administration Has participate clinical trial within 2 month Has experience blood donation 2 month blood transfusion 1 month prior study drug administration Heavy smoker 10 cigarettes/day within 3 month prior screen Continuous drinker ( 21 units/week , 1 unit = 10 g pure alcohol ) subject ca n't quit drink smoke clinical trial period Subjects eligible discretion investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>SR exenatide</keyword>
	<keyword>Peptron</keyword>
</DOC>